{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=11", "query": { "condition": "Genetic Change", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 1794, "total_pages": 180, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T00:46:19.439Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04108858", "title": "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "HER2-Positive Breast Carcinoma", "Metastatic Breast Carcinoma" ], "interventions": [ { "name": "Copanlisib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-05-20", "completion_date": "2022-04-29", "has_results": true, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04108858" }, { "nct_id": "NCT00098800", "title": "Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "brca1 Mutation Carrier", "brca2 Mutation Carrier", "Ovarian Cancer" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "FEMALE", "summary": "30 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2004-10", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2010-03-24", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098800" }, { "nct_id": "NCT03784378", "title": "Continued Access to RXDX-105", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Ovarian Cancer", "RET Gene Mutation", "BRAF Gene Mutation" ], "interventions": [ { "name": "RXDX-105", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-12-14", "completion_date": "2020-09-30", "has_results": false, "last_update_posted_date": "2025-05-15", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03784378" }, { "nct_id": "NCT05374538", "title": "VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "VIC-1911", "type": "DRUG" }, { "name": "sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vitrac Therapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-11-09", "completion_date": "2023-08-26", "has_results": true, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 5, "location_summary": "Sacramento, California • North Haven, Connecticut • Atlanta, Georgia + 2 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05374538" }, { "nct_id": "NCT06313437", "title": "Revumenib in Combination With 7+3 + Midostaurin in AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "AML, Adult", "AML With Gene Mutations", "AML", "Leukemia" ], "interventions": [ { "name": "Revumenib", "type": "DRUG" }, { "name": "Midostaurin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Richard Stone, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 22, "start_date": "2024-12-06", "completion_date": "2028-03-02", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Boston, Massachusetts", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06313437" }, { "nct_id": "NCT05498272", "title": "Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "BRCA1 Mutation", "BRCA2 Mutation", "Prostatic Adenocarcinoma", "High-Risk Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "LHRH agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rana McKay, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2023-02-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 6, "location_summary": "La Jolla, California • Baltimore, Maryland • New York, New York + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05498272" }, { "nct_id": "NCT07650357", "title": "A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Carcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "CLSP-5282", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clasp Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2026-07", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 4, "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07650357" }, { "nct_id": "NCT06599502", "title": "A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Non-Small Cell Lung Cancer (NSCLC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "AZD0022", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2024-10-18", "completion_date": "2026-01-29", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 3, "location_summary": "Duarte, California • New York, New York • Fairfax, Virginia", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06599502" }, { "nct_id": "NCT03239340", "title": "A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 154, "start_date": "2018-05-30", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 3, "location_summary": "Athens, Georgia • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "Athens", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239340" }, { "nct_id": "NCT05002270", "title": "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "NSCLC", "CRC" ], "interventions": [ { "name": "JAB-21822 (KRAS G12C inhibitor)", "type": "DRUG" }, { "name": "Cetuximab (EGFR inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-09-03", "completion_date": "2025-02-12", "has_results": false, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-11-12T00:46:19.439Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05002270" } ] }